Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?Zacks Investment Research • 09/26/25
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's DiseasePRNewsWire • 09/26/25
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for RheumatologistsGlobeNewsWire • 09/25/25
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC DubaiPRNewsWire • 09/25/25
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin QualityPRNewsWire • 09/23/25
These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big TechMarket Watch • 09/22/25
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?Zacks Investment Research • 09/16/25
AbbVie Settles Rinvoq Patent Dispute: What It Means for the StockZacks Investment Research • 09/12/25
AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.Barrons • 09/12/25
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037Reuters • 09/11/25
AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another DayInvestors Business Daily • 09/11/25